[go: up one dir, main page]

TNSN99145A1 - Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate - Google Patents

Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate

Info

Publication number
TNSN99145A1
TNSN99145A1 TNTNSN99145A TNSN99145A TNSN99145A1 TN SN99145 A1 TNSN99145 A1 TN SN99145A1 TN TNSN99145 A TNTNSN99145 A TN TNSN99145A TN SN99145 A TNSN99145 A TN SN99145A TN SN99145 A1 TNSN99145 A1 TN SN99145A1
Authority
TN
Tunisia
Prior art keywords
aminophenyle
furanyle
sulfonyle
isobutyle
benzyle
Prior art date
Application number
TNTNSN99145A
Other languages
English (en)
Inventor
Gordon Armitage Ian
David Searle Andrew
Singh Hardev
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TNSN99145A1 publication Critical patent/TNSN99145A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

-L'INVENTION PORTE SUR LE CALCIUM (3S) TETRAHYDRO-3-FURANYLE (1S,2R) -3-[[4-AMINOPHENYLE) SULFONYLE] ISOBUTYLE) AMINO]-1-BENZYLE-2- (PHOSPHONOOXY) PROPYLCARBAMATE, SUR LES PROCEDES POUR SA PREPARATION, ET SUR SON UTILISATION DANS LE TRAITEMENT DES MALADIES CAUSEES PAR LES RETROVIRUS.
TNTNSN99145A 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate TNSN99145A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
TNSN99145A1 true TNSN99145A1 (fr) 2005-11-10

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99145A TNSN99145A1 (fr) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate

Country Status (48)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1098898B1 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HK (1) HK1034261A1 (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
DK1222192T3 (da) * 1999-10-06 2008-10-20 Tibotec Pharm Ltd Hexahydrofuro-2,3-b furan-3-yl-N-3-(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino-1-benzyl-2-hydroxypropyl-carbamat som retroviral proteaseinhibitor
EP1226138B1 (fr) * 1999-10-08 2004-12-29 Affinium Pharmaceuticals, Inc. Inhibiteurs de fab i
US7049310B2 (en) * 2001-04-06 2006-05-23 Affinium Pharmaceuticals, Inc. Fab I inhibitors
JP2005523922A (ja) 2002-04-26 2005-08-11 ギリアード サイエンシーズ， インコーポレイテッド 非ヌクレオシド逆転写酵素阻害剤
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
CA2519429C (fr) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des inhibiteurs de fab i et autres antibiotiques
ATE490788T1 (de) 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
WO2004096287A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
CA2522845A1 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues de phosphonate inhibiteurs de kinase
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2004096285A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
PT1670448E (pt) * 2003-09-30 2008-02-11 Tibotec Pharm Ltd Sulfonamidas inibidoras de hcv
EP1680512A1 (fr) 2003-10-24 2006-07-19 Gilead Sciences, Inc. Procedes et compositions pour identifier des composes therapeutiques
WO2005044279A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Conjugues phosphonate / inhibiteur de purine nucleoside phosphorylase
WO2005044308A1 (fr) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Analogues phosphonates d'antimetabolites
KR20060127906A (ko) 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
DK1828167T3 (da) * 2004-06-04 2014-10-20 Debiopharm Int Sa Acrylamidderivater som antibiotiske midler
EP1778251B1 (fr) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Conjugues de phosphonate nucleosidique comme agents anti-vih
ES2341120T3 (es) 2004-11-26 2010-06-15 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatia hepatica.
JP2009518399A (ja) * 2005-12-05 2009-05-07 アフィニウム ファーマシューティカルズ， インク． Ｆａｂｉ阻害剤および抗菌剤としてのヘテロ環アクリルアミド化合物
EP2687533B1 (fr) 2006-07-20 2017-07-19 Debiopharm International SA Dérivés d'acrylamide en tant qu'inhibiteurs de FAB I
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
ES2393962T3 (es) 2008-07-08 2013-01-03 Gilead Sciences, Inc. Sales de compuestos inhibidores del VIH.
CA2998344C (fr) 2009-04-03 2020-06-02 Ocera Therapeutics, Inc. Acetate de phenyle l-ornithine et ses procedes de fabrication
EP2432788A1 (fr) * 2009-05-20 2012-03-28 Ranbaxy Laboratories Limited Fosamprenavir calcique amorphe
MX2011013129A (es) 2009-06-08 2012-03-14 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
WO2010144869A2 (fr) 2009-06-12 2010-12-16 Nektar Therapeutics Inhibiteurs de protéase
EP2448949A1 (fr) * 2009-06-30 2012-05-09 Ranbaxy Laboratories Limited Forme cristalline de fosamprénavir calcium
EP2477996A1 (fr) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Procédé pour préparer du fosamprénavir calcium
WO2011085130A1 (fr) * 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Formes solides du sel de calcium du fosamprénavir et leur procédé de synthèse
DK3127542T3 (en) 2010-01-27 2018-11-12 Viiv Healthcare Co ANTIVIRAL THERAPY
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
WO2011158259A1 (fr) * 2010-06-18 2011-12-22 Matrix Laboratories Ltd Nouveau procédé pour la préparation du (1s, 2r)-3-[[(4-aminophényl)sulfonyl] (isobutyl)amino]-1-benzyl-2-(phosphonooxy)propylcarbamate de (3s)-tétrahydrofurane-3-yle et ses sels pharmaceutiquement acceptables
US8877947B2 (en) 2010-09-10 2014-11-04 Lupin Limited Process for preparation of substantially pure fosamprenavir calcium and its intermediates
WO2012048043A1 (fr) 2010-10-06 2012-04-12 Ocera Therapeutics, Inc. Procédés de fabrication d'acétate de phényle de l-ornithine
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
US8993786B2 (en) 2011-02-10 2015-03-31 Mylan Laboratories Ltd. Crystalline fosamprenavir calcium and process for the preparation thereof
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
WO2013105118A1 (fr) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Procédé pour la synthèse d' azido-époxyde synthétique et son utilisation en tant qu'intermédiaire de la synthèse d'amprénavir et de saquinavir
EP2861608B8 (fr) 2012-06-19 2019-06-19 Debiopharm International SA Dérivés de type promédicament du (e)-n-méthyl-n-((3-méthylbenzofuran-2-yl) méthyl)-3-(7-oxo-5,6,7,8-tétrahydro-l,8-naphtyridin-3-yl)acrylamide
AU2015353703B2 (en) 2014-11-24 2021-04-01 Ucl Business Plc Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
MY189221A (en) 2016-02-26 2022-01-31 Debiopharm Int Sa Medicament for treatment of diabetic foot infections
JP7126520B2 (ja) 2017-05-11 2022-08-26 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンフェニルアセテートを製造する方法
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
SK9672000A3 (en) * 1997-12-24 2001-04-09 Vertex Pharmaceuticals Inc Ver Prodrugs of aspartyl protease inhibitors
AU2010299A (en) * 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
WO2000025784A1 (fr) * 1998-11-04 2000-05-11 Pharmacia & Upjohn Company Methode destinee a ameliorer la pharmacocinetique du tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
ES2295068T3 (es) * 1999-11-24 2008-04-16 MERCK & CO., INC. Gamma-hidroxi-2-(fluoroalquilaminocarbonil)-1-piperazinpentanamidas como inhibidores de la proteasa del vih.

Also Published As

Publication number Publication date
GEP20033030B (en) 2003-07-25
DE69904600T2 (de) 2003-11-13
GC0000105A (en) 2005-06-29
SK762001A3 (en) 2001-10-08
EP1240903A2 (fr) 2002-09-18
GT199900111A (es) 2001-01-05
ID28070A (id) 2001-05-03
AR019388A1 (es) 2002-02-13
GB9815567D0 (en) 1998-09-16
NO20010282D0 (no) 2001-01-17
NZ509291A (en) 2003-05-30
YU3401A (sh) 2005-06-10
SK285311B6 (sk) 2006-10-05
JP3437553B2 (ja) 2003-08-18
EP1098898B1 (fr) 2002-12-18
BRPI9912156B1 (pt) 2016-07-26
ZA200100417B (en) 2002-02-27
IL140824A (en) 2004-09-27
US20030100537A1 (en) 2003-05-29
DZ2845A1 (fr) 2003-12-01
NO329676B1 (no) 2010-11-29
EP1098898A1 (fr) 2001-05-16
US6514953B1 (en) 2003-02-04
JO2114B1 (en) 2000-05-21
HU229700B1 (en) 2014-05-28
MY122323A (en) 2006-04-29
PL345620A1 (en) 2002-01-02
EA003191B1 (ru) 2003-02-27
EA200100053A1 (ru) 2001-08-27
CN1324363A (zh) 2001-11-28
HK1034261A1 (en) 2001-10-19
CO5090836A1 (es) 2001-10-30
KR100694721B1 (ko) 2007-03-15
ES2189450T3 (es) 2003-07-01
IL140824A0 (en) 2002-02-10
EE200100038A (et) 2002-06-17
AP2001002039A0 (en) 2001-03-31
PL195736B1 (pl) 2007-10-31
EP1240903A3 (fr) 2003-02-12
ATE229964T1 (de) 2003-01-15
NO20010282L (no) 2001-03-07
AU766056B2 (en) 2003-10-09
MA26660A1 (fr) 2004-12-20
US20030096795A1 (en) 2003-05-22
BR9912156A (pt) 2001-04-10
DE69904600D1 (de) 2003-01-30
PT1098898E (pt) 2003-04-30
HUP0103432A3 (en) 2003-01-28
CA2337857A1 (fr) 2000-01-27
WO2000004033A1 (fr) 2000-01-27
CZ300447B6 (cs) 2009-05-20
IS5808A (is) 2001-01-12
SV1999000096A (es) 2000-07-06
CN1188422C (zh) 2005-02-09
CZ2001219A3 (cs) 2001-07-11
BG105253A (en) 2001-12-29
AU5037999A (en) 2000-02-07
PA8477801A1 (es) 2000-05-24
HUP0103432A2 (hu) 2002-04-29
OA11706A (en) 2005-01-13
DK1098898T3 (da) 2003-04-07
JP2003521447A (ja) 2003-07-15
CA2337857C (fr) 2011-01-25
PE20000869A1 (es) 2000-09-08
KR20010071952A (ko) 2001-07-31
TR200100111T2 (tr) 2002-02-21
TWI245770B (en) 2005-12-21
HRP20010046A2 (en) 2002-02-28
BRPI9912156B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
TNSN99145A1 (fr) Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate
TR199802423T2 (xx) Konsantre antikor terkibi.
MA28289A1 (fr) Immunoglobulines
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
YU7797A (sh) Kombinovana terapija za osteoporozu
SE9704546D0 (sv) Novel compounds
DE69526437D1 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
AP9801269A0 (en) Prostaglandin agonists.
DE60018085D1 (de) Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
PT1079803E (pt) Formulacoes de proteinas
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
DE59609508D1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
BR0012921A (pt) Compostos calcilìticos
ATE415960T1 (de) Toluolsulfonamid enthaltende antitumorale zusammensetzung und anwendungsverfahren dafür
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
DK0972521T3 (da) Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
CA2217463A1 (fr) Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels
HUP9904578A2 (hu) Xanomelin alkalmazása bipoláris depresszió kezelésére szolgáló gyógyszerkészítmények előállítására
EP1370697A4 (fr) Medicaments a base de peroxyredoxine pour le traitement d'infections par le vih-1, et leurs methodes d'utilisation